Drug intelligence / Profile preview

tazemetostat + tafasitamab + lenalidomide

Development stage: Unknown
Lead developer: Ipsen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

**tazemetostat + tafasitamab + lenalidomide** is a triple drug combination investigated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma who are not eligible for transplant[2][4][7]. Tazemetostat is a small molecule inhibitor of **enhancer of zeste homolog 2 (EZH2)**, a histone methyltransferase involved in epigenetic silencing and oncogenesis. Tafasitamab is a humanized monoclonal antibody targeting **CD19** on B-cells, designed to enhance antibody-dependent cellular cytotoxicity and phagocytosis. Lenalidomide is an **immunomodulatory agent** that boosts natural killer cell-mediated ADCC and has antiproliferative and pro-apoptotic activities. The combination is under phase II clinical investigation and aims to increase response rates, shrink tumors, and prolong progression-free intervals by targeting multiple mechanisms in lymphoma pathophysiology[2][4][7].

Other names: tazemetostat + tafasitamab + lenalidomide

Targets

CD19 (B lymphocyte antigen CD19)CRBN (Cereblon)EZH2 (Histone-lysine N-methyltransferase EZH2)

Beyond the preview

Go deeper on tazemetostat + tafasitamab + lenalidomide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tazemetostat + tafasitamab + lenalidomide.

Explore the full profile